Semaglutide and Kidney Protection in Type 2 Diabetes

Published in Nature Medicine (October 2026), this randomized, placebo-controlled clinical trial investigated the kidney-protective mechanisms of semaglutide in individuals with type 2 diabetes and chronic kidney disease. The 52-week study involved 106 participants and integrated advanced kidney imaging, tissue biopsy, and molecular profiling to examine treatment-related changes in kidney health.

Findings demonstrated that semaglutide was associated with reduced albuminuria, decreased kidney vascular resistance, stabilization of imaging markers associated with fibrosis, and favorable molecular changes in glomerular endothelial cells. Researchers also identified reductions in kidney-associated fat deposits, providing additional insight into potential mechanisms of kidney protection.

Dr. Matthias Kretzler was a contributing and corresponding author, participating in trial conduct and data collection. The research advances understanding of how GLP-1 receptor agonists may protect kidney function beyond their effects on blood glucose, highlighting the importance of microvascular health, endothelial cell function, and molecular pathways in chronic kidney disease.

This study provides valuable mechanistic insight into the kidney-protective effects of semaglutide and contributes to a growing understanding of therapeutic strategies for slowing kidney disease progression in individuals with type 2 diabetes.

Read the full article here.